Chemical Inhibitors of Soluble Adenylyl Cyclase (Sac)
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to a method of treating a disorder mediated by soluble adenylyl cyclase in a subject. The method involves administering to a subject an effective amount of a compound disclosed herein that modulates soluble adenylyl cyclase, under conditions effective to treat the disorder mediated by soluble adenylyl cyclase. The present invention also relates to a method of treating a disorder mediated by soluble adenylyl cyclase in a subject, where the disorder is selected from the group consisting of: learning or memory disorders, malaria, fungal infection, spinal cord injury, Alzheimer'"'"'s disease, amyotrophic lateral sclerosis, and peripheral neuropathy. The method involves modulating soluble adenylyl cyclase in the subject. Another aspect of the present invention relates to a method of modulating soluble adenylyl cyclase. The method involves contacting eukaryotic cells with a compound that modulates soluble adenylyl cyclase, under conditions effective to modulate soluble adenylyl cyclase.
8 Citations
161 Claims
-
1-42. -42. (canceled)
-
43. A method of treating a disorder mediated by a soluble adenylyl cyclase of a subject, said method comprising:
-
administering to the subject a therapeutically effective amount of a compound that modulates the soluble adenylyl cyclase, said compound having the following formula;
wherein;
R1 is H, OH, alkyloxy, or halogen;
R2 and R5 are H or halogen;
R3 is H or OH;
R4 is H, alkyloxy, or halogen;
R6 is H or alkyl; and
R7 is H or CH2R8, wherein R8 is H, alkyl, or substituted or unsubstituted phenyl, with the proviso that at least one of R1, R2, and R4 is a halogen. - View Dependent Claims (44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)
-
-
60. A method of treating a disorder mediated by a soluble adenylyl cyclase of a subject, wherein the disorder is selected from the group consisting of:
- learning or memory disorders, spinal cord injury, Alzheimer'"'"'s disease, amyotrophic lateral sclerosis, and peripheral neuropathy, said method comprising;
modulating the soluble adenylyl cyclase of the subject. - View Dependent Claims (61, 62, 63)
- learning or memory disorders, spinal cord injury, Alzheimer'"'"'s disease, amyotrophic lateral sclerosis, and peripheral neuropathy, said method comprising;
-
64. A pharmaceutical composition for treating a disorder mediated by a soluble adenylyl cyclase of a subject, comprising a therapeutically effective amount of a compound of the following formula:
-
wherein;
R1 is H, OH, alkyloxy, or halogen;
R2 and R5 are H or halogen;
R3 is H or OH;
R4 is H, alkyloxy, or halogen;
R6 is H or alkyl; and
R7 is H or CH2R8, wherein R8 is H, alkyl, or substituted or unsubstituted phenyl, with the proviso that at least one of R1, R2, and R4 is a halogen, and one or more pharmaceutically acceptable excipients. - View Dependent Claims (65, 66, 67, 68, 69)
-
-
66. The pharmaceutical composition of claim 64, wherein the subject is an eukaryotic organism.
-
67. The pharmaceutical composition of claim 66, wherein the eukaryotic organism is a mammal.
-
68. The pharmaceutical composition of claim 67, wherein the mammal is a human.
-
69. The pharmaceutical composition of claim 68, wherein the human disorder is selected from the group consisting of:
- learning or memory disorders, male fertility/sterility, glaucoma, metabolic acidosis/alkalosis, diabetes, metabolic disorders, breathing disorders, insulin resistance, hyperinsulinemia, spinal cord injury, Alzheimer'"'"'s disease, amyotrophic lateral sclerosis, and peripheral neuropathy.
-
70. A method of treating a parasitic infection in a subject, the method comprising:
administering to the subject a therapeutically effective amount of a compound that inhibits adenylyl cyclase of the parasite. - View Dependent Claims (71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 98)
-
88. A method of treating a fungal infection in a subject, the method comprising:
administering to the subject a therapeutically effective amount of a compound that inhibits adenylyl cyclase of the fungal organism. - View Dependent Claims (89, 90, 91, 92, 93, 94, 95, 96, 97)
-
99. A pharmaceutical composition for treating a parasitic infection in a subject comprising:
-
a therapeutically effective amount of a compound that inhibits adenylyl cyclase of the parasite; and
a pharmaceutically acceptable carrier. - View Dependent Claims (100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116)
-
-
117. A pharmaceutical composition for treating a fungal infection in a subject comprising, an effective amount of a compound that inhibits adenylyl cyclase of the fungal organism;
- and
a pharmaceutically acceptable carrier. - View Dependent Claims (118, 119, 120, 121, 122, 123, 124, 125, 126, 127)
- and
- 128. A method of treating a parasitic infection in a subject mediated by adenylyl cyclase of a parasite in a subject, comprising, inhibiting the adenylyl cyclase of the parasite.
-
136. A method of treating a fungal infection in a subject mediated by adenylyl cyclase of the fungal organism in a subject, comprising:
inhibiting adenylyl cyclase of the fungal organism. - View Dependent Claims (137, 138, 139, 140, 141, 142, 143)
-
144. A method of identifying a compound that is a selective inhibitor of adenylyl cyclase of a parasite, the method comprising:
measuring the inhibitory effect of the compound against one or more human adenylyl cyclases, measuring the inhibitory effect of the compound against adenylyl cyclase of a parasite, and identifying the compound having greater inhibitory effect against adenylyl cyclase of a parasite than against human adenylyl cyclase. - View Dependent Claims (145, 146, 147)
-
148. A method of identifying a compound that is a selective inhibitor of adenylyl cyclase of a fungal organism, the method comprising:
measuring the inhibitory effect of the compound against one or more human adenylyl cyclases, measuring the inhibitory effect of the compound against adenylyl cyclase of a fungal organism, and determining whether the compound has a greater inhibitory effect against adenylyl cyclase of a fungal organism than against human adenylyl cyclase. - View Dependent Claims (149, 150, 151)
-
152. A method of inhibiting adenylyl cyclase of a parasite, the method comprising:
contacting eukaryotic cells with a compound that inhibits adenylyl cyclase of the parasite. - View Dependent Claims (153, 154, 155)
-
156. A method of inhibiting adenylyl cyclase of a fungal organism, the method comprising:
- contacting eukaryotic cells with a compound that inhibits adenylyl cyclase of the fungal organism.
- View Dependent Claims (157, 158, 159)
-
160. A method of inhibiting adenylyl cyclase of a parasite, the method comprising:
contacting the parasite with a compound that inhibits adenylyl cyclase of the parasite.
-
161. A method of inhibiting adenylyl cyclase of a fungal organism, the method comprising:
contacting the fungal organism with a compound that inhibits adenylyl cyclase of the fungal organism.
Specification